Cullinan Therapeutics, Inc. (CGEM) Institutional Ownership

Ownership Summary

The institutional landscape for Cullinan Therapeutics, Inc. (NASDAQ:CGEM) includes 142 filers as of the latest reporting cycle ending September 2025.

• The collective stake of institutional investors in Cullinan Therapeutics moved to 103.1% in September 2025, a shift up from the 102.7% reported for June 2025.
• Quarterly data indicates a -0.19% shift in institutional share volume, and the annual owner count reflects an increase of 4.41%.
• Of these 142 institutional investors, 77 increased their holdings in Cullinan Therapeutics, while 41 of them reduced positions, and 24 investors maintained their exposure.
• The total number of shares held by institutions in Cullinan Therapeutics decreased to 60.92Mn as of September 2025, a net change of down by 116.18K shares quarter on quarter, and down 4.70Mn shares year over year.
• With 7.65Mn shares, MPM BioImpact LLC commands the largest institutional position in Cullinan Therapeutics as of September 30, 2025, equating to 12.95% of the company.
• Among the most significant buyers of Cullinan Therapeutics during September 2025 were Lynx1 Capital Management LP (1.37Mn), GOLDMAN SACHS GROUP INC (281.82K), JANE STREET GROUP, LLC (266.40K), Kynam Capital Management, LP (206.17K), RENAISSANCE TECHNOLOGIES LLC (194.88K).
• Leading sellers of Cullinan Therapeutics stock in September 2025 included DEERFIELD MANAGEMENT COMPANY, L.P. (928.54K), FRANKLIN RESOURCES INC (812.12K), CITADEL ADVISORS LLC (762.74K), Caption Management, LLC (729.14K), MARSHALL WACE, LLP (331.14K).
• The top 10 institutional holders of Cullinan Therapeutics for the quarter ending September 2025 included MPM BioImpact LLC (7.65Mn), Lynx1 Capital Management LP (5.77Mn), BVF INC/IL (5.75Mn), BlackRock, Inc. (4.17Mn), VANGUARD GROUP INC (2.94Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (2.93Mn), Blue Owl Capital Holdings LP (2.51Mn), Kynam Capital Management, LP (2.30Mn), CITADEL ADVISORS LLC (1.98Mn), ORBIMED ADVISORS LLC (1.92Mn).